Malignant Glioma with Neuronal Marker Expression : A Clinicopathological Study of 18 Cases.
10.3340/jkns.2016.59.1.44
- Author:
Hong Rye KIM
1
;
Jae Jun LEE
;
Jung Il LEE
;
Do Hyun NAM
;
Yeon Lim SUH
;
Ho Jun SEOL
Author Information
1. Department of Neurosurgery, Konyang University Hospital, Konyang University School of Medicine, Daejeon, Korea.
- Publication Type:Original Article
- Keywords:
Malignant gliomas;
Neuronal marker;
Methylation status of O6-methylguanine-DNA methyltransferase;
Expression of isocitrate dehydrogenase 1;
1p and 19q
- MeSH:
Classification;
Diagnosis;
Disease-Free Survival;
Glioblastoma;
Glioma*;
Humans;
Isocitrate Dehydrogenase;
Medical Records;
Methylation;
Multivariate Analysis;
Neurons*
- From:Journal of Korean Neurosurgical Society
2016;59(1):44-51
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Malignant gliomas with neuronal marker expression (MGwNM) are rare and poorly characterized. Increasingly diverse types of MGwNM have been described and these reported cases underscore the dilemmas in the classification and diagnosis of those tumors. The aim of this study is to provide additional insights into MGwNM and present the clinicopathological features of 18 patients. METHODS: We reviewed the medical records of 18 patients diagnosed as MGwNM at our institute between January 2006 and December 2012. Macroscopic total resection was performed in 11 patients (61%). We evaluated the methylation status of O6-methylguanine-DNA methyltransferase (MGMT) and expression of isocitrate dehydrogenase 1 (IDH-1) in all cases, and deletions of 1p and 19q in available cases. RESULTS: The estimated median overall survival was 21.2 months. The median progression-free survival was 6.3 months. Six patients (33%) had MGMT methylation but IDH1 mutation was found in only one patient (6%). Gene analysis for 1p19q performed in nine patients revealed no deletion in six, 19q deletion only in two, and 1p deletion only in one. The extent of resection was significantly correlated with progression free survival on both univariate analysis and multivariate analysis (p=0.002 and p=0.013, respectively). CONCLUSION: In this study, the overall survival of MGwNM was not superior to glioblastoma. The extent of resection has a significant prognostic impact on progression-free survival. Further studies of the prognostic factors related to chemo-radio therapy, similar to studies with glioblastoma, are mandatory to improve survival.
